Share

October 2015; 2 (5) Clinical/Scientific NotesOpen Access

Plasticity-related gene 5: A novel surface autoantigen in paraneoplastic cerebellar degeneration

Marleen H. van Coevorden-Hameete, Esther de Graaff, Maarten J. Titulaer, Esther Hulsenboom, Lidia Sabater, Casper C. Hoogenraad, Peter A. Sillevis Smitt
First published September 24, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000156
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
442

Share

Article Information

vol. 2 no. 5 e156
DOI: 
https://doi.org/10.1212/NXI.0000000000000156
PubMed: 
26445730
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received June 23, 2015
  • Accepted in final form August 5, 2015
  • First Published September 24, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Marleen H. van Coevorden-Hameete, MD,
    2. Esther de Graaff, PhD,
    3. Maarten J. Titulaer, MD, PhD,
    4. Esther Hulsenboom, BSc,
    5. Lidia Sabater, BSc,
    6. Casper C. Hoogenraad, PhD and
    7. Peter A. Sillevis Smitt, MD, PhD
  1. Marleen H. van Coevorden-Hameete, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Esther de Graaff, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1)co-investor: the detection anti-DNER antibodies

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Maarten J. Titulaer, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Serve on the scientific advisory board of MedImmune LLC.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Sun Pharma, travel grant for lecturing in India

    Editorial Boards:

    1. (1) Neurology: Neuroimmunology & Neuroinflammation, since June 2014

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) supported by the Netherlands Organisation for Scientific Research (NWO, Veni incentive)

    Research Support, Academic Entities:

    1. (1) Currently supported by an ErasmusMC fellowship

    Research Support, Foundations and Societies:

    1. (1) supported by the Dutch Epilepsy Foundations, projectnumber 14-19.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Esther Hulsenboom, BSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lidia Sabater, BSc,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Casper C. Hoogenraad, PhD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Peter A. Sillevis Smitt, MD, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Peter Sillevis Smitt is co-inventor of a pending patent on the detection anti-DNER

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Peter Sillevis Smitt received a research grant from Euroimmun.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Biology (M.H.v.C.-H., E.d.G., C.C.H.), div Cell Biology, Utrecht University, Utrecht, the Netherlands; Department of Neurology (M.H.v.C.-H, M.J.T., E.H., P.A.S.S.), Erasmus Medical Center, Rotterdam, the Netherlands; and Service of Neurology Hospital Clinic (L.S.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  1. Correspondence to Dr. Smitt: p.sillevissmitt{at}erasmusmc.nl
View Full Text

Article usage

Article usage: September 2015 to September 2022

AbstractFullPdfSource
Sep 2015117105Highwire
Oct 201510810728Highwire
Oct 201505413pmc
Nov 20152262Highwire
Nov 2015011826pmc
Dec 2015944Highwire
Dec 20150202pmc
Jan 20161287Highwire
Jan 201601310pmc
Feb 20161213Highwire
Feb 2016072pmc
Mar 20161756Highwire
Mar 20160116pmc
Apr 20162786Highwire
Apr 2016072pmc
May 20161656Highwire
May 2016085pmc
Jun 20161342Highwire
Jun 2016053pmc
Jul 20162011Highwire
Jul 2016063pmc
Aug 20161440Highwire
Aug 2016061pmc
Sep 2016741Highwire
Sep 2016092pmc
Oct 2016831Highwire
Oct 2016074pmc
Nov 20161044Highwire
Nov 2016061pmc
Dec 2016821Highwire
Dec 2016030pmc
Jan 2017712Highwire
Jan 2017076pmc
Feb 2017332Highwire
Feb 2017043pmc
Mar 20171130Highwire
Mar 2017070pmc
Apr 2017900Highwire
Apr 2017343pmc
May 2017521Highwire
May 2017011pmc
Jun 2017911Highwire
Jun 2017345pmc
Jul 2017140Highwire
Jul 2017011pmc
Aug 2017722Highwire
Aug 2017111pmc
Sep 20171020Highwire
Sep 2017265pmc
Oct 20171021Highwire
Oct 2017022pmc
Nov 2017811Highwire
Nov 2017133pmc
Dec 2017461Highwire
Jan 2018940Highwire
Feb 2018363Highwire
Mar 2018263Highwire
Apr 20181112Highwire
Apr 2018111pmc
May 201821203Highwire
Jun 20183122Highwire
Jun 2018222pmc
Jul 20186163Highwire
Aug 20183221Highwire
Aug 2018011pmc
Sep 20184101Highwire
Oct 20184112Highwire
Nov 20182311Highwire
Dec 201816192Highwire
Jan 20194123Highwire
Feb 20195180Highwire
Mar 20192126Highwire
Apr 2019233Highwire
May 2019494Highwire
Jun 2019383Highwire
Jul 2019375Highwire
Aug 2019793Highwire
Sep 2019344Highwire
Oct 2019190Highwire
Nov 2019366Highwire
Dec 2019150Highwire
Jan 2020463Highwire
Feb 20202115Highwire
Mar 2020447Highwire
Apr 2020063Highwire
May 20200117Highwire
Jun 2020041Highwire
Jul 2020082Highwire
Aug 2020031Highwire
Sep 20205126Highwire
Oct 2020266Highwire
Nov 2020265Highwire
Dec 2020390Highwire
Jan 202161111Highwire
Feb 2021072Highwire
Mar 2021362Highwire
Apr 2021350Highwire
May 20216143Highwire
Jun 20213164Highwire
Jul 202131112Highwire
Aug 20213443Highwire
Sep 20212107Highwire
Oct 202112218Highwire
Nov 202101115Highwire
Dec 20214229Highwire
Jan 20220174Highwire
Feb 20221115Highwire
Mar 20221195Highwire
Apr 2022071Highwire
May 202221010Highwire
Jun 20220133Highwire
Jul 20221135Highwire
Aug 20223205Highwire
Sep 202202310Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Topics Discussed

Alert Me

Advertisement